source
- Roche licenses Rona's ALK7 obesity candidate in $1.2 billion dealRoche has agreed to license an RNAi drug candidate targeting ALK7 from Chinese biotech Rona Therapeutics, with an upfront payment of $100 million and potential milestones up to $1.06 billion. The…
- Study urges regulators to adopt cloud platforms to speed drug approvalsA new study led by Nina Cauchon of Amgen and co-authors, published in the Journal of Pharmaceutical Sciences, calls for broader use of cloud-based platforms by regulatory agencies. The authors arg…